Objective: The aim of this study was to highlight that concurrent administration of the common lipid-lowering agent fenofibrate may lead to false-positive amphetamine results in often-used immunoassay-based urine drug screens. It also aimed to show that there are significant moral and clinical challenges associated with the interpretation of such results amongst psychiatric inpatients. Conclusions: It is evident that different pathology laboratories may utilise different commercial urine drug-screen immunoassays in their toxicology analysis, with variability in the test specificities. Despite the relatively high prevalence of substance misuse in the population of psychiatric inpatients, there exists a need for increased vigilance towards the possibility of false-positive amphetamine results owing to likely cross-reactivity of fenofibrate with the test reagents. In cases where there is uncertainty when correlating clinically, or where false positives are suspected, gold-standard urine-sample analysis by mass spectrometry should be considered, particularly when the consequences for patients may include restrictive measures.
Introduction
Urine drug screens (UDS) are commonly used in the setting of inpatient psychiatric treatment to assess drug use, reasons for behavioural changes and compliance with medical advice. Results may be used in numerous ways to assist with patient management, including restriction of leave as a means to minimise likelihood of exposure to illicit recreational substances such as amphetamines during treatment. Given the high prevalence of amphetamine misuse within numerous psychiatric patient groups, 1 the UDS is an important test to include when working with these patients. The high prevalence, however, also has the effect of raising the positive predictive value of UDS results which may lull clinicians into a sense of confidence that a positive result is automatically a true positive. In reality true positives are defined by the gold standard of mass spectrometry, which requires an additional pathology test on the urine sample to be ordered. Unless specifically requested, most laboratories in Australia will not perform mass spectrometry.
Pathology laboratories in Australia often utilise immunoassay-based tests for the UDS, with high sensitivities approaching 100%, although specificities are lower. For example, using a cut-off amphetamine concentration of 500 ng/mL as the minimum for a positive UDS result, the Thermo Scientific © DRI ® immunoassay claims a sensitivity of 100% and a specificity of 65%, 2 while the Thermo Scientific © Cloned Enzyme Donor Immunoassay (CEDIA) ® immunoassay claims a sensitivity of 100% and a specificity of 68% 3 in detecting methamphetamine. The Australian national standard AS4308 for pathology laboratories 4 is slightly more stringent in its mandate for compliance, with a UDS cut-off value of 300 ng/mL for positive detection of amphetamine-type stimulants. Under these standards, the sensitivity increases further, while the specificity can be expected to be slightly lower than that quoted by the manufacturer at a cut-off of 500 ng/mL.
False positives are thought to occur when there is crossreactivity between UDS test reagent antibodies and molecules in the urine sample which have similar chemical structures to the target molecule (amphetamine). In some cases, the drug metabolite rather than the parent molecule is responsible for the cross-reactivity, resulting in a false positive. Numerous substances have been reported to cross-react in UDS immunoassays. The anti-reflux medication ranitidine and the antidepressant bupropion may both test positive in a UDS for amphetamine, thereby reducing the specificity 5 of that particular test. Other substances known to be responsible for false positives include chlorpromazine, promethazine and labetalol. 6 It should be noted, however, that cross-reactivity is assay specific, as different test reagent antibodies may be used by different manufacturers. This means that each particular UDS immunoassay will have its own list of substances which are known to cross-react, so a (false) positive with one immunoassay may not necessarily appear as a positive result in a UDS test by a different manufacturer.
In this case series, we illustrate difficulties faced when relying upon the UDS to assist in clinical decision making. Specifically, this article highlights the variability in accurate urinary detection of amphetamines in patients being administered fenofibrate. In contemporary psychiatric practice, fenofibrate may be prescribed to address iatrogenic triglyceride elevations proactively secondary to the use of mood stabilisers and antipsychotics, 7 especially when lifestyle modifications such as exercise and dietary adjustments are inadequate to bring about the desired effect. It is believed that fenofibrate, or a metabolite of it, has a molecular structure bearing similarity to amphetamine which may produce false-positive UDS readings. [8] [9] [10] [11] In these research articles, mass spectrometry was used as a gold standard to confirm or refute presumptive positive results based upon the initial UDS.
Case 1: a proven false positive (pathology laboratory A)
An Australian man in his 40s with paranoid schizophrenia and type 2 diabetes was prescribed fenofibrate (145 mg in the morning), metformin extended release (2 g at night), ramipril (2.5 mg in the morning) and risperidone depot injection (50 mg fortnightly). He took unescorted ward leave and underwent a random UDS upon his return, which tested positive for amphetamines. As per ward policy, his leave was cancelled for one day before re-instatement. After further leave, a UDS upon his return to the ward again returned a positive result. This time leave was cancelled for three days, and he had another UDS collected on the fourth day just prior to leaving the ward, with the aim of establishing a negative result before his leave. The result was again positive for amphetamines. This was accepted as still being within the possible time frame for amphetamine detoxification in the body. However, it also raised suspicions of a falsepositive result. The patient remained resolute that he did not misuse substances or consume any over-the-counter ephedrine-containing cold and flu medication which may have otherwise explained the results. He returned from leave and again a positive UDS result was obtained. Further discussion with the hospital chemical pathologist suggested that fenofibrate may have led to a false positive. This urine sample was analysed with mass spectrometry which showed a negative reading for amphetamines. The patient was provided with an explanation of the findings, as well as an apology to facilitate re-establishment of the therapeutic alliance. His leave entitlements were reinstated, and the ward policy for interpretation of positive UDS readings was reviewed.
Case 2: a presumptive false positive (pathology laboratory A)
An Englishman in his 30s experiencing a first episode of psychosis with elevated mood was prescribed zuclopenthixol depot injection (200 mg fortnightly), sodium valproate (500 mg in the morning and 1 g at night), lorazepam (2 mg twice daily) and fenofibrate (145 mg in the morning). Of note, fenofibrate had only been commenced one day before the UDS. As he was previously known to be non-adherent to ward rules for unescorted leave, his nurse ordered a random UDS upon his return. A positive reading was obtained for amphetamines. There was, however, no clinical evidence to suggest acute amphetamine misuse, and the patient denied usage. As such, no mass spectrometry testing was undertaken, and no changes to his treatment plan or leave entitlements were made.
Case 3: a presumptive true negative (pathology laboratory B)
A Middle Eastern man in his 40s with paranoid schizophrenia, type 2 diabetes, hypercholesterolemia and hypertension was admitted into the psychiatric ward with a relapse of psychosis following a period of medication non-adherence. He was prescribed candesartan (8 mg in the morning), atenolol (50 mg in the morning), rosuvastatin (5 mg at night), metformin (500 mg at night), fenofibrate (145 mg in the morning), omeprazole (20 mg in the morning), vitamin D (1000 IU in the morning) and clozapine (350 mg at night). A UDS was requested as part of his work up for psychosis upon initial presentation to the emergency department. His UDS returned a negative result. This correlated clinically with him having no convincing features of amphetamine intoxication, and there was no supporting history of amphetamine use. Given the high test sensitivity, no confirmatory analysis with mass spectrometry was indicated.
Discussion
Laboratory A uses the CEDIA UDS for amphetamines which has known cross-reactivity with fenofibrate and its metabolites. 8, 10, 11 The product information supplied with the test kit does not indicate that fenofibrate may lead to false-positive results, 3 although a document from the manufacturer (identified in an online search) indicated that a metabolite of fenofibrate may lead to false-positive results. 12 Laboratory B used a different method, the Roche ONLINE Amphetamine Immunoassay (Roche Diagnostic Systems, Inc., Somerville, NJ), for which falsepositive results with fenofibrate have not been described.
Immunoassay-based UDS techniques have advantages of being fast, cheap and in some cases portable which can allow testing to be done by the bedside. However, the assays have a limitation of being class specific and will only detect molecules bearing a similar structure but not necessarily the specific drug of interest. For example, a UDS may return a positive result for benzodiazepines, but it does not necessarily provide any information on the specific benzodiazepine used or the quantity consumed. Most UDS test kits are comprised of a number of individual tests, each for a different drug class such as tricyclics, benzodiazepines, amphetamines or opiates. Any drug outside of the classes being tested in that particular UDS assay will not be detected (i.e. they can be considered partial drug screens).
An ideal starting point for clinicians is an awareness of the limitations of such screening tests, followed by availability of information on assay sensitivity and specificity, likely causes of false-positive results and then consideration of mass spectrometry for confirmation if indicated. To this end, close collaboration between mental-health clinicians administering the UDS and pathology laboratory staff is essential, particularly with regard to the validity and performance of the assay in use at their laboratory. It would also be beneficial to have education sessions conducted jointly by pathology and psychiatry departments in order to educate doctors, nurses and allied health professionals in teaching hospitals as well as community mental-health centres. In forensic and custodial settings, parole officers may also benefit from such sessions.
The appropriate use of mass spectrometry can be especially beneficial and informative for agencies monitoring drug use in their client groups, including community mental-health centres, inpatient units, drug and alcohol treatment providers and forensic services. Clients are often required to register negative urinary toxicology readings for incentives to be offered such as granting of leave or an increased number of take-home opiate substitution doses. Aside from missing out on incentives, clients are also likely to face increased levels of stigma whenever unconfirmed presumptive positive UDS results are encountered. Although a scenario of initial diagnostic testing with mass spectrometry might be attractive, it is not realistic in the majority of clinical settings owing to the significant costs involved and the requirement for laboratory expertise. By contrast, a urinary drug immunoassay can be performed by any pathology laboratory or even at the point of care, at lower prices and with round-the-clock availability.
This case series highlights both the need for caution when dealing with positive amphetamine results in urine toxicology tests in patients taking fenofibrate, as well as the limitations of UDS tests in the absence of mass spectrometry to provide confirmation. As in all aspects of medicine, careful history taking and the development of a therapeutic alliance is often as important as more objective factors such as laboratory tests. 13, 14 This is particularly so in contemporary psychiatric practice where patients are encouraged to be open about their drug use. It is therefore important that clinicians consider all the evidence, including limitations in the analytical specificity of UDS tests, whenever a patient may be on the receiving end of punitive measures or deprivations of liberty contingent upon test results.
